4.4 Article

Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis

期刊

ARTHRITIS CARE & RESEARCH
卷 64, 期 12, 页码 1819-1828

出版社

WILEY-BLACKWELL
DOI: 10.1002/acr.21764

关键词

-

资金

  1. Genentech
  2. NIH [AR053351]
  3. Agency for Healthcare Research and Quality [R01HS018517]
  4. Pfizer
  5. BMS
  6. Crescendo
  7. Abbott
  8. Roche/Genentech
  9. UCB
  10. Centocor
  11. Consortium of Rheumatology Researchers of North America
  12. Amgen
  13. AstraZeneca
  14. Bayer

向作者/读者索取更多资源

Objective To estimate the incidence and risk factors for gastrointestinal (GI) perforation among patients with rheumatoid arthritis (RA). Methods Claims from employer health insurance plans were used to identify RA patients and those hospitalized for upper or lower GI perforation. GI perforation cases were identified using both a sensitive and a specific definition. A Cox model using fixed and time-varying covariates was used to evaluate the risk of GI perforation. Results Among 143,433 RA patients, and using a maximally sensitive GI perforation definition, 696 hospitalizations with perforation were identified. The rate of perforation was 1.70 per 1,000 person years (PYs; 95% confidence interval [95% CI] 1.581.83), and most perforations (83%) occurred in the lower GI tract. The rate of perforation was lower when a more specific GI perforation definition was used (0.87; 95% CI 0.780.96 per 1,000 PYs). Age and diverticulitis were among the strongest risk factors for perforation (diverticulitis hazard ratio [HR] 14.5 [95% CI 11.817.7] for the more sensitive definition, HR 3.9 [95% CI 2.55.9] for the more specific definition). Among various RA medication groups and compared to methotrexate, the risk of GI perforation was highest among patients with exposure to nonsteroidal antiinflammatory drugs (NSAIDs), concomitant nonbiologic disease-modifying antirheumatic drugs, and glucocorticoids. Biologic agents without glucocorticoid exposure were not a risk factor for perforation. Conclusion GI perforation is a rare but serious condition that affects patients with RA, most frequently in the lower GI tract. Clinicians should be aware of risk factors for GI perforation when managing RA patients, including age, history of diverticulitis, and use of glucocorticoids or NSAIDs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据